CTRI/2020/09/027827已完成未知
A Single-Blind, Randomized, Placebo Controlled, Multiple Dose, Safety Study of Bacillus subtilis PLSSC in Healthy Human Volunteers
Advanced Enzyme Technologies Ltd0 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy human in the age range of 18 to 65 years (both inclusive) 2. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study. 3. Have voluntarily given written informed consent to participate in this study. 4. Be of normal health as determined by medical history, have sitting systolic blood pressure of >=90 mmHg to <=120 mmHg and diastolic blood pressure of >=60 mmHg or <= 80 mmHg, pulse rate 60 to 90 bpm, clinical examination and laboratory investigations performed within 14 days prior to the commencement of the study. 5. Not on medication for chronic diseases (thyroid, diabetes, CNS depressants, CNS stimulants, asthma, CVD, COPD, or any other diseases which requires daily consumption of medicine for the same)
排除标准
- •1. History of hypersensitivity to any drug or history of allergic reactions/atopy. 2. Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations. 3. Presence of disease markers of HIV (Self-reported) 4. Presence of values, which are out of acceptable limits for hemoglobin, RBC count, hematocrit, activated partial thromboplastin time (aPTT), prothrombin time (PT), total white blood cells count, differential WBC count or platelet count. 5. Presence of values which are out of acceptable limits for blood urea nitrogen (BUN), serum creatinine, uric acid, sodium, potassium, calcium, phosphorus, chloride, bicarbonate, alkaline phosphatase (ALP), aspartate amino transferase (AST), alanine amino transferase (ALT), total bilirubin, gamma glutamyl transpeptidase (GGT), albumin, globulin, total protein, cholesterol, triglycerides, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), glucose,. Clinically abnormal chemical and microscopic examination of urine. 6. History of or any complaints suggestive of gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological (including generalized or partial epilepsy), endocrine, vision abnormality, rheumatological, urogenital or hematological disease. 7. Presence of significant infection or known inflammation by selfdeclaration by subject or diagnosed by PI. 8. Presence of acute gastrointestinal symptoms at the time of screening and/or admission (e.g., nausea, vomiting, diarrhea, heart burn). 9. Presence of chronic constipation (less than 3 times a week for 12 weeks) at the time of screening and/or admission. 10. Inability to communicate well with investigator (i.e. language problem, poor mental development, psychiatric illness or poor cerebral function) that may impair the ability to provide, written informed consent. 11. History of joint pain, stiffness and reduced mobility. 12. Use of tobacco in any form (including cigarette smoking) in the last 6 months 13. History of drug dependence or habitual alcohol abuser. 14. Use of any regular medication (OTC or prescription) within 14 days or any drug metabolizing enzyme modifying medications within 30 days prior to Day 1 of this study. 15. History of intake of chronic medication. 16. Participation in any clinical trial within 12 weeks preceding Day 1 of this study. 17. Volunteers who, through completion of this study, would have donated and/or lost more than 350 mL of blood in the past 3 months. 18. On any other probiotic or antibiotic mediations 19. Pregnant or breast-feeding women or women with child-bearing potential not using medically acceptable methods of contraception (Self-reported).
研究者
相似试验
未知
1 期
A Randomized, Single-Blind, Placebo-Controlled, Multi-Centre, PhaseI Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM PatientsType 2 DiabetesJPRN-jRCT2080220768AstraZeneca
进行中（未招募）
1 期
A Randomized, Single Blind, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEUCTR2005-002485-11-GBGlaxoSmithKline Research & Development Ltd.
进行中（未招募）
不适用
A Randomized, Single Blind, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEUCTR2005-002485-11-GRGlaxoSmithKline Research & Development Ltd.90
进行中（未招募）
1 期
A study to investigate the safety and efficacy of two approved drugs, niclosamide and camostat, administered in combination and compared to placebo in COVID-19 patientsSARS-Coronavirus 2 disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-002233-15-DECharité Research Organisation GmbH40
已完成
1 期
A phase I clinical trial to study the safety and tolerability of multiple doses of a new compound, RBx 10017609, in healthy volunteersCTRI/2009/091/000173Ranbaxy Laboratories Ltd. Plot No. 20, Sector 18 Udyog Vihar Industrial Area Gurgaon 122015. Haryana INDIA42